| First Author | Park HY | Year | 2014 |
| Journal | J Clin Invest | Volume | 124 |
| Issue | 11 | Pages | 4976-88 |
| PubMed ID | 25295537 | Mgi Jnum | J:217605 |
| Mgi Id | MGI:5615042 | Doi | 10.1172/JCI75667 |
| Citation | Park HY, et al. (2014) Pellino 1 promotes lymphomagenesis by deregulating BCL6 polyubiquitination. J Clin Invest 124(11):4976-88 |
| abstractText | The signal-responsive E3 ubiquitin ligase pellino 1 (PELI1) regulates TLR and T cell receptor (TCR) signaling and contributes to the maintenance of autoimmunity; however, little is known about the consequence of mutations that result in upregulation of PELI1. Here, we developed transgenic mice that constitutively express human PELI1 and determined that these mice have a shorter lifespan due to tumor formation. Constitutive expression of PELI1 resulted in ligand-independent hyperactivation of B cells and facilitated the development of a wide range of lymphoid tumors, with prominent B cell infiltration observed across multiple organs. PELI1 directly interacted with the oncoprotein B cell chronic lymphocytic leukemia (BCL6) and induced lysine 63-mediated BCL6 polyubiquitination. In samples from patients with diffuse large B cell lymphomas (DLBCLs), PELI1 expression levels positively correlated with BCL6 expression, and PELI1 overexpression was closely associated with poor prognosis in DLBCLs. Together, these results suggest that increased PELI1 expression and subsequent induction of BCL6 promotes lymphomagenesis and that this pathway may be a potential target for therapeutic strategies to treat B cell lymphomas. |
